Stem Cell TV | Video / Media News

Page 112 3 4..10 20..»

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is…

Posted: May 31, 2025 at 2:45 am

30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers 30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers

Original post:
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is...

Posted in Global News Feed | Comments Off

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Posted: May 31, 2025 at 2:45 am

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines.

Go here to see the original:
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Posted in Global News Feed | Comments Off

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

Posted: May 31, 2025 at 2:44 am

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024

Continued here:
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

Posted in Global News Feed | Comments Off

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

Posted: May 31, 2025 at 2:44 am

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:

Read more here:
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

Posted in Global News Feed | Comments Off

Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant…

Posted: May 31, 2025 at 2:44 am

SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers

Go here to see the original:
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant...

Posted in Global News Feed | Comments Off

Shareholder Update

Posted: May 31, 2025 at 2:44 am

May 30, 2025

Link:
Shareholder Update

Posted in Global News Feed | Comments Off

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

Posted: May 31, 2025 at 2:44 am

BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025.

See the original post here:
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

Posted in Global News Feed | Comments Off

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Posted: May 31, 2025 at 2:44 am

CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time.

More here:
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Posted in Global News Feed | Comments Off

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Posted: May 31, 2025 at 2:44 am

HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the acceptance of three abstracts for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. The abstracts highlight Processa’s pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri), showcasing both preclinical and clinical advances.

See original here:
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Posted in Global News Feed | Comments Off

PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

Posted: May 31, 2025 at 2:44 am

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect consumers and patients.

More:
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla

Posted in Global News Feed | Comments Off

Page 112 3 4..10 20..»